Guess which ASX 300 stock is jumping amid huge profit growth

The company is forecasting its profits to more than double in the first half.

| More on:
A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nanosonics Ltd (ASX: NAN) shares are having a strong session on Thursday.

In early trade, the ASX 300 stock is up 6% to $3.97.

Why is this ASX 300 stock is jumping?

Investors have been buying the infection prevention company's shares this morning following the release of a half-year update.

According to the release, Nanosonics is expecting to report a sizeable increase in revenue and profits for the half after returning to form in FY 2025.

For the six months ended 31 December, the ASX 300 stock expects total revenue to be approximately $93.6 million. This is up 18% from $79.6 million in the prior corresponding period. It is also up 4% from the $90.4 million recorded in the second half of FY 2024.

Commenting on its top line performance during the half, the company's CEO and president, Michael Kavanagh, said:

The expected first half revenue result of $93.6m represents a good start to the year up 18% compared to pcp and 4% compared to H2 FY24. Revenue growth was primarily driven by 20% growth (compared to pcp) in our consumables and service annuity revenue streams. The total number of trophon units sold in the first half was broadly in line with internal forecasts and was similar to the total number sold in the pcp, with overall capital revenue up 11% compared to pcp.

Strong profit growth

The company's gross margin for the half is expected to be approximately 78.5%. This is down from 79.7% in the prior corresponding period but up from 76.3% in the second half of FY 2024.

Nanosonics' operating expenses are expected to be approximately $66.7 million for the half. This is up 10% from the prior corresponding period and 3% on the previous half.

Nevertheless, this couldn't stop the ASX 300 stock from delivering strong profit growth. Management expects a profit before tax of approximately $10.9 million for the six months. This is more than double the $4.9 million recorded in the prior corresponding period and is up from $8.1 million in second half of FY 2024.

CEO Michael Kavanagh revealed that some of this profit growth comes from one-offs. He explains:

As a result of the increased first half revenue, the business expects to deliver profit before tax (PBT) of $10.9 million for the half. The expected PBT result includes a gain of approximately $1.3 million (compared to a $0.4 million loss in H1 FY24) due to the AUD exchange rate moving from 0.66 on 30 June 2024 to 0.62 on 31 December 2024. This movement created an unrealised FX gain on US dollar-denominated assets, partially offset by the group's hedging activities.

Outlook

Kavanagh believes that Nanosonics' first half performance means that it is on track to "achieve revenue, gross margin and operating expenses in FY25 around the top of each of the ranges for those measures specified in Nanosonics' FY25 outlook statement."

This includes total revenue growth of 8% to 12%, a gross margin of 77% to 79%, and operating expense growth of 6% to 10%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »

shadow of a man looking out a window with arrows signifying falling share price
Healthcare Shares

Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Top broker names the best ASX healthcare shares to buy in FY26

Bell Potter has good things to say about these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is jumping on record quarter?

This stock reported record sales during the past three months.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

If you haven’t heard of this fast-rising ASX 200 stock yet, that’s about to change.

Read more »